SeroHub Launched: Interactive Dashboard Comparing COVID-19 Seroprevalence Studies
, by DCEG Staff
COVID-19 SeroHub is designed to address questions about changes in prevalence over time, types of serology tests being utilized, and whether a specific state has an active serology study in place.
The COVID-19 Seroprevalence Studies Hub (SeroHub) was developed by epidemiologists, data scientists, data engineers and other researchers at the Centers for Disease Control and Prevention (CDC), the National Cancer Institute, and the National Institute of Allergy and Infectious Diseases (NIAID), parts of the National Institutes of Health, to compare COVID-19 seroprevalence studies across the country. Explore the COVID-19 SeroHub site.
Neal D. Freedman, Ph.D., M.P.H., led the NCI team made up of epidemiologists and developers in the Center for Biomedical Informatics and Information Technology, in collaboration with experts at NIAID and CDC. COVID-19 SeroHub went live on December 1, 2020, with data from seroprevalence studies conducted across the U.S. by CDC, NIH, state and local health departments, universities, and other sources. Additional studies will be added as they become available. The site will systematically identify published and ongoing SARS-CoV-2 seroprevalence studies via an interactive dashboard to visualize seroprevalence estimates over time and by geography, population, and other factors. The goal is to address questions about changes in prevalence over time, types of serology tests being utilized, and whether a specific state has an active seroprevalence study in place.
These data will have tremendous value for public health officials at the national, state, and local levels. In addition to informing public health interventions, the information from SeroHub will inform the design and implementation of vaccine trials, improve predictive models of the pandemic, identify scientific gaps and disparities, and ultimately, enable scientists to distinguish natural versus vaccine immunity.